SLC5A2 and type 2 diabetes mellitus: Additionally, a randomized controlled trial and a single-arm study have corroborated the positive impact of SGLT2 inhibitors on the cognitive function of elderly patients with T2DM and non-diabetic individuals aged 55 or older, respectively [122, 123].